Jupiter Neurosciences, Inc. (JUNS)
BiotechSign Signal Grade
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Pipeline Overview
- Therapeutic Focus
- Neurosciencesrc
Clinical Trial Activity
(ClinicalTrials.gov aggregate)
ClinicalTrials.gov aggregate as of 2026-10-06. ClinicalTrials.gov
Dilution Risk
HIGH DILUTION RISKDilution score: 59/100 (HIGH), cash runway not available
Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score
Short Interest
Short interest: ?% of float, squeeze risk: LOW
FINRA short sale data. FINRA short interest
Recent News & SEC Filings
- Sector Update: Healthcare Stocks Mixed Late Afternoon
- Sector Update: Healthcare Stocks Mixed Tuesday Afternoon
- Jupiter Neurosciences Announces First Patient Dosed in Phase 2a RESET Trial in Parkinson’s Disease and Exploration of Strategic Options to Maximize Shareholder Value
- Weekly Roundup on the Cannabis Sector & Psychedelic Sector
- Real Parkinson’s Disease Hope from Jupiter Neurosciences
- Psychedelic Therapy Meets M&A: Fireside Chat with Jupiter Neurosciences CEO Christer Rosén & President Alison Silva
- Jupiter Neurosciences Signs ALA-002 License Agreement Worth Up to $100 Million (NASDAQ:JUNS)
- Jupiter Neurosciences (NASDAQ: JUNS) Signs Definitive Agreement for Exclusive U.S. Rights to ALA-002 in Transaction Valued at Up to $100 Million
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for Jupiter Neurosciences, Inc..
Full JUNS Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.